Infectious complications of biologic therapy in patients with rheumatoid arthritis;Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider Arthritis

Zeitschrift fur Rheumatologie

Volumn 69, Issue 10, 2010, Pages 879-888

  Meyer Olson, D ^a   Hoeper, K ^a   Schmidt, R E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatitis B virus infection; Immunosuppression; Rheumatoid arthritis; Risk of infection; Tuberculosis; Vaccination

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; BIOLOGICAL THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTIOUS COMPLICATION; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; TUBERCULOSIS; VIRUS REACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; RISK; RISK FACTORS; T-LYMPHOCYTES;

EID: 78650111541     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-010-0677-2     Document Type: Article

References (29)

1. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
2. Wollenhaupt J, Alten R, Backhaus M et al (2009) Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. Akt Rheumatol 234-239
3. Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287-2293
4. Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380-386
5. Gluck T, Muller-Ladner U (2008) Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 46:1459-1465 (Pubitemid 351589953)
6. Doran MF, Crowson CS, Pond GR et al (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294-2300
7. Curtis JR, Patkar N, Xie A et al (2007) Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56:1125-1133 (Pubitemid 46608637)
8. Patkar NM, Teng GG, Curtis JR, Saag KG (2008) Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol 20:320-326 (Pubitemid 351483323)
9. Zink A, Strangfeld A, Schneider M et al (2006) Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54:3399-3407 (Pubitemid 44737150)
10. Listing J, Strangfeld A, Kary S et al (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403-3412 (Pubitemid 41612206)
11. Nam JL, Winthrop KL, Vollenhoven RF van et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976-986
12. Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25-32
13. Strangfeld A, Listing J, Herzer P et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-744
14. Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834-4840
15. Furst DE, Keystone EC, Fleischmann R et al (2010) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69 (Suppl 1):i2-i29
16. Diel R, Hauer B, Loddenkemper R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 68:411-416
17. Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784 (Pubitemid 351847559)
18. Calabrese LH, Zein NN, Vassilopoulos D (2006) Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 65:983-989 (Pubitemid 44133258)
19. Carroll MB, Forgione MA (2010) Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 29:1021-1029
20. Cornberg M, Protzer U, Dollinger MM et al (2007) Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 45:1281-1328
21. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352-1355
22. Bengtsson C, Kapetanovic MC, Kallberg H et al (2010) Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 69:1831-1833
23. Fomin I, Caspi D, Levy V et al (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65:191-194 (Pubitemid 43131992)
24. Elkayam O, Caspi D, Reitblatt T et al (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283-288 (Pubitemid 38280827)
25. Elkayam O, Yaron M, Caspi D (2002) Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 61:623-625 (Pubitemid 34717774)
26. Fendler C (2009) Impfempfehlungen für Patienten mit entzündlich-rheumatischen Erkrankungen (http://dgrh.de/impfempfehlung.html) : Projektgruppe Diagnose und Therapierichtlinien/Deutsche Gesellschaft für Rheumatologie
27. STIKO (2005) Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz Stand: November 2005. 2005:1-12
28. STIKO (2010) Mitteilung der Ständigen Impfkommission am Robert Koch-Institut Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2010. Epidemiologisches Bulletin. 2010:279-298
29. Winthrop KL, Furst DE (2010) Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy. Ann Rheum Dis 69:1735-1737